Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma

Published:2023-07-14 Issue:13 Volume:149 Page:12479-12487
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Pan Songsong,Zheng Jiaxi,Shi Changsheng

Funder

Zhejiang Provincial Medicine and Health Science and Technology Program

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05050-0.pdf

Reference23 articles.

1. Chang Y, Jeong SW, Young Jang J, Kim YJ (2020) Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci 21(21):8165

2. Chen YL, Ko CJ, Chien SY et al (2011) Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited. J Gastroenterol Hepatol 26(5):851–857

3. Craciun L, de Wind R, Demetter P et al (2020) Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 20(1):135

4. Kondo M, Morimoto M, Kobayashi S et al (2019) Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 19(1):954

5. Kudo M (2020) Limited impact of Anti-PD-1/PD-L1 monotherapy for hepatocellular carcinoma. Liver Cancer 9(6):629–639

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study;Annals of Hepatology;2024-09

2. Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis;Oncology Letters;2024-06-26

3. Dihydrotanshinone Enhances The Anticancer Effects of Sorafenib on Hepatocellular Carcinoma by Inhibiting Akt Signaling Pathway Activation;PROG BIOCHEM BIOPHYS;2024